LOS ANGELES, Jan. 24, 2023 (GLOBE NEWSWIRE) — Glancy Prongay & Murray LLP (“GPM”) reminds investors of what’s to come March 6, 2023 Deadline for Filing a Complaint by Lead Plaintiff in the Class Action Complaint Filed on Behalf of Investors Claiming BioLineRx Ltd. (“BioLine” or the “Company”) purchased or otherwise acquired BLRX American Depositary Shares (“ADSs”) between February 23, 2021 and September 19, 2022inclusive (the “Class Period”).

If you have suffered a loss on your BioLine investments or would like to inquire about the possibility of making claims to recover your loss under the federal securities laws, you may submit your contact information at www.glancylaw.com/cases/biolinerx-ltd/. You can also contact GPM’s Charles H. Linehan at 310-201-9150, toll free at 888-773-9224, or email at shareholders@glancylaw.com to learn more about your rights.

On September 15, 2022, BioLine announced that Kreos Capital VII Aggregator SCSP will provide the Company with up to $40 million in aggregate principal amount of term loans.

On September 19, 2022, BioLine announced a registered direct offering of approximately 14 million ADSs and warrants to purchase ADSs at a total price of $1.10 per ADS and associated warrants.

As a result of this news, the company’s share price fell by 33% to close at $1.02 per share on September 19, 2022.

The Complaint filed in this Class Action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and failed to disclose material adverse facts about the Company’s business, operations and prospects. Specifically, Defendants failed to disclose to investors that: (1) the Company was not adequately funded to develop Motixafortide while advancing other pipeline programs; (2) BioLine would require a loan from Kreos Capital VII Aggregator SCSP in aggregate principal amount of up to US$40 million and then also a US$15 million securities offering to facilitate the commercial launch of Motixafortide; and (3) as…